Trastuzumab and HER2 Targeted Cancer Treatment
/ Jan Trøst Jørgensen
Insights into Tumor Microenvironment Antigens and Immunomodulation
/ Mads Hald Andersen
DESTINY-Breast03 study: trastuzumab deruxtecan versus trastuzumab emtansine
/ Guiseppe Curigliano